Owner Scorecard


← Japan catalog ← 4452 Manual 4503 → ← 4151 Pharmaceuticals 4503 →

4502 · Takeda Pharmaceutical

Pharma Consumer & brand IFRS
Latest filing: FY2026 annual securities report (有価証券報告書) · EDINET

The numbers below are read directly from Takeda Pharmaceutical’s EDINET filing, in yen. The Japanese-language narrative is not machine-read; the short business note that follows is written and reviewed by hand, grounded in the filing and the company’s established facts. Find it on EDINET (code 4502) →

The business in brief

What it is
Takeda is Japan's largest pharmaceutical company and a global biopharmaceutical maker. It discovers, manufactures, and sells branded, patent-protected prescription medicines, reaching patients through doctors, hospitals, pharmacies, and health systems worldwide. It earns its money by spending heavily on research and acquisitions to build a portfolio of drugs, then selling the ones that win approval at high margins for as long as their patents and exclusivity hold.
What moves the needle
A branded-drug business is a portfolio of wasting assets: each medicine enjoys franchise-like pricing while its patent holds, then meets generic competition that collapses the price, so the test is whether the pipeline and acquired products replace the revenue lost at the patent cliff faster than the cliff erodes it. Watch the gross margin for the pricing power that branded exclusivity is supposed to confer, and watch whether reinvested R&D and dealmaking actually convert into approved, durable sellers rather than write-offs. The bad case is plain: a debt-funded build-out of intangibles, with rights and royalties owed to partners, that must keep earning its keep against expiring exclusivity and a balance sheet that carries net debt. The figures — margins, returns on capital, and the debt load — are in the record below.

Written and reviewed by hand, grounded in the filing and the company’s established facts.

I

The record

What the business has done across the cycle, read straight from the EDINET filing: the multi-year record, and the walk from reported profit to the cash an owner could take out.

The record, 2017–2026

realized figures from each filing · older years to the left
2017’172018’182019’192020’202021’212022’222023’232024’242025’252026’26
Income statement
¥1.73T¥1.77T¥2.10T¥3.29T¥3.20T¥3.57T¥4.03T¥4.26T¥4.58T¥4.51TRevenueRevenue
67%69%66%65%Gross marginGross mgn
29%27%24%24%SG&A / revenueSG&A/rev
3%4%3%3%R&D / revenueR&D/rev
¥70.3B¥241.8B¥237.7B¥100.4B¥509.3B¥460.8B¥490.5B¥214.1B¥342.6B¥6.2BOperating incomeOp. inc.
4.1%13.7%11.3%3.1%15.9%12.9%12.2%5.0%7.5%0.1%Operating marginOp. mgn
¥114.9B¥186.9B¥135.2B¥44.2B¥376.0B¥230.1B¥317.0B¥144.1B¥107.9B(¥152.4B)Net incomeNet inc.
Cash flow & returns
¥261.4B¥377.9B¥328.5B¥669.8B¥1.01T¥1.12T¥977.2B¥716.3B¥1.06T¥1.04TOperating cash flowOp. cash
¥182.1B¥247.7B¥583.6B¥559.7B¥583.2B¥664.4B¥728.0B¥761.4B¥721.1BDepreciationDeprec.
¥146.4B¥8.8B(¥54.4B)¥41.9B¥75.3B¥309.9B(¥4.3B)(¥155.7B)¥187.9B¥472.7BWorking capital & otherWC & other
¥67.0B¥77.7B¥127.1B¥111.2B¥123.3B¥140.7B¥175.4B¥200.8B¥176.0BCapexCapex
3.8%3.7%3.9%3.5%3.5%3.5%4.1%4.4%3.9%Capex / revenueCapex/rev
¥310.8B¥250.8B¥542.7B¥899.7B¥999.9B¥836.5B¥540.9B¥856.4B¥865.4BOwner earningsOwner earn.
17.6%12.0%16.5%28.1%28.0%20.8%12.7%18.7%19.2%Owner earnings marginOE mgn
¥310.8B¥250.8B¥542.7B¥899.7B¥999.9B¥836.5B¥540.9B¥856.4B¥865.4BFree cash flowFCF
17.6%12.0%16.5%28.1%28.0%20.8%12.7%18.7%19.2%Free cash flow marginFCF mgn
¥142.2B¥141.9B¥143.0B¥282.6B¥283.4B¥283.7B¥279.4B¥287.2B¥302.5B¥311.9BDividends paidDiv. paid
¥23.1B¥18.8B¥1.2B¥3.7B¥2.1B¥77.5B¥26.9B¥2.3B¥51.9B¥51.6BBuybacksBuybacks
2%8%2%1%5%5%5%2%2%0%ROICROIC
8%12%3%1%7%5%8%4%2%-2%Return on equityROE
−2%3%−0%−5%2%−1%1%−4%−3%−6%Retained to equityRetained/eq
Balance sheet
¥88.8B¥294.5B¥702.1B¥709.4B¥1.50T¥849.7B¥533.5B¥457.8B¥478.7B¥802.5BCash & investmentsCash+inv
¥158.1B¥129.9B¥141.8B¥145.1B¥125.7B¥114.5B¥59.8B¥47.9B¥37.0B¥43.4BReceivablesReceiv.
¥46.3B¥37.7B¥36.8B¥30.2B¥33.0B¥43.7B¥39.2B¥62.1B¥76.9B¥87.9BInventoryInvent.
¥204.4B¥167.5B¥178.6B¥175.3B¥158.8B¥158.2B¥99.0B¥110.1B¥114.0B¥131.2BOperating working capitalOper. WC
¥687.1B¥1.08T¥2.99T¥2.47T¥2.71T¥2.59T¥2.40T¥2.56T¥2.52T¥3.09TCurrent assetsCur. assets
¥901.2B¥354.0B¥1.21T¥1.17T¥1.83T¥1.15T¥1.00T¥1.17T¥1.89T¥2.04TCurrent liabilitiesCur. liab.
0.8×3.0×2.5×2.1×1.5×2.3×2.4×2.2×1.3×1.5×Current ratioCurr. ratio
¥1.03T¥4.24T¥4.01T¥4.03T¥4.41T¥4.79T¥5.41T¥5.32T¥5.81TGoodwillGoodwill
¥4.35T¥4.11T¥13.79T¥12.82T¥12.91T¥13.18T¥13.96T¥15.11T¥14.25T¥15.51TTotal assetsAssets
¥1.19T¥985.7B¥5.75T¥5.09T¥4.64T¥4.35T¥4.38T¥4.84T¥4.52T¥4.88TTotal debtDebt
¥1.10T¥691.1B¥5.05T¥4.38T¥3.13T¥3.50T¥3.85T¥4.39T¥4.04T¥4.08TNet debt / (cash)Net debt
16.3×24.1×4.9×0.7×4.3×4.2×4.9×2.2×3.0×0.1×Interest coverageInt. cov.
¥1.53T¥1.57T¥4.65T¥4.72T¥5.17T¥4.29T¥4.21T¥4.09T¥6.94T¥7.43TShareholders’ equityEquity
Per share
1.58B1.59B1.57B1.58B1.58B1.58B1.58B1.58B1.59B1.59BShares out (diluted)Shares
¥1095.51¥1113.98¥1340.07¥2087.82¥2028.57¥2255.65¥2545.34¥2694.46¥2879.76¥2831.60Revenue / shareRev/sh
¥72.70¥117.58¥86.38¥28.07¥238.52¥145.40¥200.35¥91.04¥67.84¥-95.77EPS (diluted)EPS
¥195.58¥160.26¥344.25¥570.75¥631.92¥528.66¥341.83¥538.29¥543.87Owner earnings / shareOE/sh
¥195.58¥160.26¥344.25¥570.75¥631.92¥528.66¥341.83¥538.29¥543.87Free cash flow / shareFCF/sh
¥89.96¥89.28¥91.34¥179.26¥179.75¥179.28¥176.59¥181.49¥190.14¥196.01Dividends / shareDiv/sh
¥42.16¥49.63¥80.62¥70.54¥77.90¥88.89¥110.86¥126.21¥110.61Cap. spending / shareCapex/sh
¥968.00¥985.24¥2969.43¥2996.42¥3281.58¥2714.42¥2658.30¥2583.51¥4359.08¥4669.00Book value / shareBVPS

Share counts before 2019 are restated ×2 for a stock split, so per-share figures sit on one basis.

Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+11.1%/yr+6.9%/yr
Owner earnings / share+13.6%/yr (8-yr)−1.0%/yr
Dividends / share+9.0%/yr+1.7%/yr
Capital spending / share+12.8%/yr (8-yr)+9.4%/yr
Book value / share+19.1%/yr+7.3%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2026 the business turned a ¥152.4B loss into ¥865.4B of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2026FY2025FY2024FY2023FY2022
Reported net income(¥152.4B)¥107.9B¥144.1B¥317.0B¥230.1B
Depreciation & amortizationnon-cash charge added back+¥721.1B+¥761.4B+¥728.0B+¥664.4B+¥583.2B
Working capital & othertiming of cash in and out, other non-cash items+¥472.7B+¥187.9B−¥155.7B−¥4.3B+¥309.9B
Cash from operations¥1.04T¥1.06T¥716.3B¥977.2B¥1.12T
Capital expenditurecash put back in to keep running and to grow−¥176.0B−¥200.8B−¥175.4B−¥140.7B−¥123.3B
Owner earnings¥865.4B¥856.4B¥540.9B¥836.5B¥999.9B
Owner-earnings marginowner earnings ÷ revenue19%19%13%21%28%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

II

Quality & stewardship

Returns, the balance sheet, and stewardship. The same checks the US pages run, in yen.

Owner’s Scorecard

FY2026 Annual securities report · source on EDINET →

Will it survive?

  • Does not cover its interest
    Operating income ¥6.2B ÷ interest expense ¥123.8B
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • How heavy is the debt, net of cash? ¥4.08T · 656.2× operating profit
    Heavy net debt
    Cash ¥595.1B + ST investments ¥207.4B − debt ¥4.88T
    What this means

    Netting ¥802.5B of cash and short-term investments against ¥4.88T of debt leaves ¥4.08T owed, about 656.2× a year's operating profit (785.2× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average through the cycle
    10-yr median, range 0%–8%; 0% latest = NOPAT ¥4.9B ÷ invested capital ¥11.72T
    Industry peers: median 21%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 0% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • High through the cycle
    9-yr median margin, range 12%–28%; latest ¥865.4B = operating cash ¥1.04T − maintenance capex ¥176.0B
    Industry peers: median 36%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 19% of revenue this year, a 19% median across 9 years.

  • Loss, but cash-generative
    Net income (¥152.4B) · cash from operations ¥1.04T
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.

How is the cash used?

  • Returns about half
    Dividends + buybacks ¥363.5B ÷ Owner Earnings ¥865.4B
    What this means

    Of ¥865.4B Owner Earnings, ¥363.5B (42%) went back to shareholders, ¥311.9B dividends, ¥51.6B buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 0.24×
    Harvesting
    Capex ¥176.0B ÷ depreciation ¥721.1B
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Durability & moat, 2017–2026

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 9 of 10
    What this means

    Lost money in 1 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 10 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 10% → 4% (3-yr avg ends)
    What this means

    Through the cycle the operating margin slipped — about 10% early to 4% lately, median 7% — competition or costs are biting in.

  • Reinvestment, incremental ROIC 0%
    What this means

    Reinvested capital came back at only a modest incremental return — near the cost of capital, where extra growth adds little per dollar. The record shows whether it is a soft stretch or a thinning moat.

  • Owner earnings growth +15%/yr
    What this means

    Owner earnings grew about 15% a year over the record.

  • Worst year 2026 · 0.1% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Dividend record rising
    What this means

    Paid and raised the dividend across the record, the continuity Graham prized.

All figures as filed; the source filing is linked above.

How the cash was used, 2018–2026

Over the record, the business generated ¥7.30T of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested¥1.20T · 16%
  • Dividends¥2.32T · 32%
  • Buybacks¥236.1B · 3%
  • Retained (debt / cash)¥3.55T · 49%
  • Returned to owners¥2.55T

    42% of the owner earnings the business produced over the span, ¥2.32T as dividends and ¥236.1B as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span debt rose ¥3.90T and cash and short-term investments rose ¥507.9B.

  • Average price paid for buybacks

    Buybacks ran ¥236.1B over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count0.1%

    The diluted count barely moved (1589M to 1591M): buybacks roughly offset the stock issued to staff.

  • Dividend record¥196.01/sh

    Paid in 9 of the years on record, the per-share dividend growing about 10% a year. It was never cut over the span.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Inverting the record

Invert: instead of why Takeda Pharmaceutical is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2026.

1 of the 5 tests turned up something to look into; the other 4 came back clean.

  • Look hereDid debt outgrow the business?¥1.19T → ¥4.88T

    Debt rose from ¥1.19T to ¥4.88T while owner earnings went from about ¥368.1B to ¥754.2B — about 3.2 years of owner earnings in debt then, about 6.5 now: measured against what the business earns, the balance sheet carries more debt than it did. Debt raised for buybacks or deals rather than growth is the kind that bites in a downturn.

And these came back clean
  • Is it less profitable than it was?
  • Did the share count rise anyway?
  • Did reported profit become cash?
  • Did receivables and inventory outpace sales?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

III

The price

What a price would have to assume, set against the record above.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Takeda Pharmaceutical has delivered.

¥

Through the cycle, Takeda Pharmaceutical earns about ¥842.2B on its 18.7% median owner-earnings margin. This year’s 19.2% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’22→’26−2%/yr
Owner-earnings growth · ’18→’26+15%/yr
Owner-earnings yield
P/E (3-yr earnings ’24–’26)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings ¥865.4B on 1591M diluted shares; net debt ¥4.08T. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Figures from EDINET, the Financial Services Agency’s disclosure system, the same kind of filing the US pages draw from EDGAR. A separate pool: these names never pass through the US industry classifier.

Manual order: ← 4452 its page in the Manual 4503 →

Industry order: ← 4151 the Pharmaceuticals chapter 4503 →